Citeer als: (2024, april) BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002). https://geertdevuyst.be/publicatie/2024-vriens-bhv-2100-a-first-in-class-trpm3-antagonist-for-the-treatment-of-pain-s13-002/
BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002)
Artikel Engels Opgeleid
TitelBHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002)Auteur(s)Vriens, J., Vanherck, J., Marchand, A., Carr, B. R., Dubowchik, G. M., Caldwell, R. W., Granit, V., Marcin, L. R., Pirman, D., Chaltin, P., & Voets, T.PublicatieNeurologyVolume102Uitgave nummer17_supplement_1Publicatiejaar2024DOIhttps://doi.org/10.1212/wnl.0 ... UitgeverOvid Technologies (Wolters Kluwer Health)Citeer alsVriens, J., Vanherck, J., Marchand, A., Carr, B. R., Dubowchik, G. M., Caldwell, R. W., Granit, V., Marcin, L. R., Pirman, D., Chaltin, P., & Voets, T. (2024). BHV‑2100, a First‑in‑class TRPM3 Antagonist for the Treatment of Pain (S13.002). Neurology, 102(17_supplement_1). https://doi.org/10.1212/wnl.0000000000206209